ClinicalTrials.gg
RecruitingNCT07551804Updated Jul 22, 2026

Safety, Pharmacokinetic (PK) Profile and Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone Deficiency

A Phase 2 interventional study of Inpegsomatropin Injection and Placebo for Inpegsomatropin Injection in Adult Growth Hormone Deficiency, sponsored by Xiamen Amoytop Biotech Co., Ltd.. Recruiting at 6 sites in China. Open to male participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Xiamen Amoytop Biotech Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
Male
01

Study summary

This is a multiple-dose, dose-escalation, randomized, double-blind, placebo-controlled phase Ⅱa clinical trial. A total of 36 adult participants with growth hormone deficiency will be enrolled sequentially in ascending dose cohorts, and within each dose cohort, participants will be randomized in a 3:1 ratio.

02

Conditions studied

  • Adult Growth Hormone Deficiency

Browse trials for

Keywords

  • Inpegsomatropin Injection
  • Pharmacokinetic
  • Safety
  • Adults With Growth Hormone Deficiency
03

In context

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

This study's planned enrollment of 36 is below the median of 60 across 169 interventional studies indexed under Dwarfism, Pituitary.

Browse Dwarfism, Pituitary studies →

Lead sponsor

Xiamen Amoytop Biotech Co., Ltd. is the lead sponsor of 32 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male study participants aged ≥ 18 years and \< 80 years at the time of signing the form (ICF);
  • Study participants meeting the criteria for adult growth hormone deficiency (AGHD):

Patients with a peak GH level \< 5 μg/L measured by insulin tolerance test (ITT); OR Patients with an IGF-1 level below -2.0 SDS for age and sex at screening (see Appendix 4);

  • No systemic treatment with growth hormone or growth hormone secretagogues within 6 months prior to entering the screening period;
  • For patients with any other pituitary hormone deficiency who are on hormone replacement therapy (HRT) at screening, HRT must have been stable for at least 3 months;
  • Study participants must agree to use reliable measures with their spouses from - Study participants fully understand the purpose, nature, methods and potential adverse reactions of the trial, voluntarily participate in the study, and have signed the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Individuals with known or suspected to the product or its ;
  • Patients with severe malnutrition as judged by the investigator, or with a \< 18.5 kg/m² at screening;
  • Patients with active or a history of malignancy; or with thyroid nodules classified as TI-RADS grade ≥ 4a on thyroid ultrasound; or with high-risk or suspected malignant nodules detected on chest CT; or with abnormal tumor markers at screening;
  • For patients with a history of pituitary adenoma or other benign intracranial tumors:

    1. Surgical resection of pituitary adenoma or other benign intracranial tumors within 12 months prior to screening;
    2. Evidence of growth of pituitary adenoma or other benign intracranial tumors within 12 months prior to screening (must be confirmed by two postoperative MRI scans, with the most recent MRI scan performed ≤ 6 months before the screening period);
  • Patients with abnormal liver or renal function at screening ( > 3×, Cr > 1.5×ULN);
  • Patients testing positive for surface antigen (HBsAg), virus antibody (anti-HCV), or antibody (anti-HIV) at screening;
  • Patients with a clinically significant change in body weight within 6 months prior to screening as judged by the investigator, or with a self-reported body weight change of ≥ 10% compared to 6 months before screening;
  • Patients with unstable control of diabetes mellitus within 3 months prior to screening ( ≥ 7.5% at screening), or with significant adjustment of hypoglycemic medication dose or change in therapeutic drug type, or with severe diabetic complications as judged by the investigator;
  • Patients with cardiac insufficiency classified as class ≥ III;
  • Patients with a history of acromegaly or gigantism;
  • Patients with mental disability or language impairment that prevents full participation in the trial;
  • Individuals who have participated in any clinical trial of investigational medicinal products (as a trial participant) and received investigational intervention within 3 months prior to screening;
  • Other conditions deemed unsuitable for enrollment by the investigator.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    A group: Inpegsomatropin Injection low dose

    Drug: Inpegsomatropin Injection

  • Placebo comparator
    A group:Placebo for Inpegsomatropin Injection low dose

    Drug: Placebo for Inpegsomatropin Injection

  • Experimental
    B group: Inpegsomatropin Injection middle dose

    Drug: Inpegsomatropin Injection

  • Placebo comparator
    B group:Placebo for Inpegsomatropin Injection middle dose

    Drug: Placebo for Inpegsomatropin Injection

  • Experimental
    C group: Experimental:telpegfilgrastim Injection high

    Drug: Inpegsomatropin Injection

  • Placebo comparator
    C group:Placebo for Inpegsomatropin Injection high dose

    Drug: Placebo for Inpegsomatropin Injection

Interventions

  • Inpegsomatropin Injection,initial dose1mg/0.25ml, s.c. ,once a week

  • DrugPlacebo for Inpegsomatropin Injection

    Placebo for Inpegsomatropin Injection,initial dose0.25ml, s.c. ,once a week

  • Inpegsomatropin Injection,initial dose 2mg/0.5ml, s.c. ,once a week

  • DrugPlacebo for Inpegsomatropin Injection

    Placebo for Inpegsomatropin Injection,initial dose 0.5ml, s.c. ,once a week

  • Inpegsomatropin Injection,initial dose 4mg/1ml, s.c. ,once a week

  • DrugPlacebo for Inpegsomatropin Injection

    Placebo for Inpegsomatropin Injection,initial dose 1.0ml, s.c. ,once a wee

06

What researchers measure

Primary outcomes

  1. Adverse Event

    Time frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37

  2. Serious Adverse Event

    Time frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37

  3. Number of Participants with Abnormal Laboratory Parameters Findings

    Time frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37

  4. HR (bpm)

    Time frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37

  5. PR (ms)

    Time frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37

  6. QRS (ms)

    Time frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37

  7. QT (ms)

    Time frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37

  8. QTc (ms)

    Time frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37

  9. Number of participants with clinically significant changes in imaging examinations

    Time frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37

  10. body weight

    Time frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37

  11. body Mass Index

    Time frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37

  12. body temperature

    Time frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37

  13. pulse

    Time frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37

  14. blood pressure

    Time frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37

  15. Respiration

    Time frame: Day -1,Weeks 1, 3, 5, 9, 17, 25, 29, 37

  16. Trunk fat percentage

    Time frame: Week 25

  17. Trunk fat mass

    Time frame: Week 25

  18. Total fat mass

    Time frame: Week 25

  19. Visceral adipose tissue (VAT)

    Time frame: Week 25

  20. Lean body mass (LBM)

    Time frame: Week 25

  21. Bone mineral density (BMD)

    Time frame: Week 25

  22. Quality of life score (QoL score)

    Time frame: Week 25

  23. BMI

    Time frame: Week1Day1,Week25Day1

  24. Change from baseline in waist-to-hip ratio

    Time frame: Week3Day1,Week25Day1

  25. IGF-I /IGFBP-3

    Time frame: Week1Day1,Week25Day1

  26. Cmax

    Time frame: Week1Day1,Week25Day1

  27. Cmin

    Time frame: Week1Day1,Week25Day1

  28. Tmax

    Time frame: Week1Day1,Week25Day1

  29. AUC0-t

    Time frame: Week1Day1,Week25Day1

  30. AUC0-∞

    Time frame: Week1Day1,Week25Day1

  31. AUC0-tau

    Time frame: Week1Day1,Week25Day1

  32. Rac_Cmax

    Time frame: Week1Day1,Week25Day1

  33. Rac_AUC0-tau

    Time frame: Week1Day1,Week25Day1

  34. CL/F

    Time frame: Week1Day1,Week25Day1

  35. Vz/F

    Time frame: Week1Day1,Week25Day1

  36. DF

    Time frame: Week1Day1,Week25Day1

  37. t1/2

    Time frame: Week1Day1,Week25Day1

  38. ADA

    Time frame: Week1Day1,Week29Day1

  39. NAb

    Time frame: Week1Day1,Week29Day1

07

Study locations

6 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2026
First posted
Apr 27, 2026
StartActual
Jun 10, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jun 30, 2028
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07551804
Responsible party
Sponsor
First posted
Apr 27, 2026
Start date
Jun 10, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Jul 22, 2026

Study contacts

Yiming Li, Ph.D
Contact
yimingli@fudan.edu.cn
13501936597
Yiming Li
principal investigator · Huashan Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inpegsomatropin

Start the discussion